NCT07341737 2026-01-15SL-28 for Advanced Solid TumoursSecond Life TherapeuticsPhase 1/2 Not yet recruiting60 enrolled
NCT05544929 2026-01-06A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersNovartisPhase 1 Active not recruiting126 enrolled
NCT05379985 2025-11-12Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRevolution Medicines, Inc.Phase 1/2 Recruiting754 enrolled
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT05462717 2024-11-07Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1 Active not recruiting222 enrolled
NCT02900664 2022-03-29A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)NovartisPhase 1 Completed283 enrolled
NCT00753415 2015-03-17A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)Merck Sharp & Dohme LLCPhase 1 Completed37 enrolled 10 charts